The data presented within this paper is the first report of a humanized domain-deleted monoclonal antibody (HuCC49ΔCH2) to be utilized in a radioimmunotherapeutic (RIT) application with 213Bi. An initial study indicated that 111In-HuCC49ΔCH2 targets the subcutaneously implanted human colon carcinoma xenograft, LS-174T, when injected via a peritoneal route. The HuCC49ΔCH2 was then radiolabeled with 213Bi, an α-emitting radionuclide with a half-life of 45. 6 minutes, and evaluated for therapeutic efficacy. Dose titration studies indicated that a single dose of 500-1000 μCi, when injected by an intraperitoneal route, resulted in the growth inhibition or regression of the tumor xenograft. The radioimmunotherapeutic effect was found to be dose-dependent. Specificity of the therapeutic efficacy was confirmed in a subsequent experiment with athymic mice bearing TAG-72 negative MIP (human colorectal) xenografts. A preliminary study was also performed to assess a multiple-dose administration of 213Bi-HuCC49ΔCH2. Doses (500 μCi) were administered at 14-day intervals after tumor implantation. A reduction in volume and/or delay in tumor growth was evident following the second and third injections of 213Bi-HuCC49ΔCH2. As further validation of the use of 213Bi-HUCC49ΔCH2 for RIT, a study using 131I was conducted. The overall survival of mice receiving 213Bi-HuCC49ΔCH2 was greater than those that received 131I-HUCC49ΔCH2.
|Original language||English (US)|
|Number of pages||13|
|Journal||Cancer Biotherapy and Radiopharmaceuticals|
|State||Published - 2004|
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Cancer Research